Cargando…
Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer
INTRODUCTION: In January 2020, the coronavirus disease 2019 (COVID-19) outbreak in Italy necessitated rigorous application of more restrictive safety procedures in the management and treatment of patients with cancer to ensure patient and staff protection. Identification of respiratory syndrome coro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308791/ https://www.ncbi.nlm.nih.gov/pubmed/32567505 http://dx.doi.org/10.1177/0300891620935983 |
_version_ | 1783549069196525568 |
---|---|
author | Scarlattei, Maura Baldari, Giorgio Silva, Mario Bola, Stefano Sammartano, Antonino Migliari, Silvia Graziani, Tiziano Cidda, Carla Sverzellati, Nicola Ruffini, Livia |
author_facet | Scarlattei, Maura Baldari, Giorgio Silva, Mario Bola, Stefano Sammartano, Antonino Migliari, Silvia Graziani, Tiziano Cidda, Carla Sverzellati, Nicola Ruffini, Livia |
author_sort | Scarlattei, Maura |
collection | PubMed |
description | INTRODUCTION: In January 2020, the coronavirus disease 2019 (COVID-19) outbreak in Italy necessitated rigorous application of more restrictive safety procedures in the management and treatment of patients with cancer to ensure patient and staff protection. Identification of respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was a challenge during the pandemic owing to a large number of asymptomatic or mildly symptomatic patients. METHODS: We report 5 patients with unknown SARS-CoV-2 infection undergoing positron emission tomography (PET)/computed tomography (CT) with radiopharmaceuticals targeting different tumor processes: (18)F-FDG, (18)F-choline (FCH), and (68)Ga-PSMA. RESULTS: In all patients, PET/CT showed increased tracer uptake in the lungs corresponding to CT findings of SARS-CoV-2 pneumonia. Quantitative assessment of tracer uptake showed more elevated values for the glucose analogue (18)F-FDG (mean SUVmax 5.4) than for the other tracers (mean SUVmax 3.5). CONCLUSIONS: Our findings suggest that PET/CT is a sensitive modality to hypothesize SARS-CoV-2 pneumonia in patients with cancer, even when asymptomatic. More data are needed to verify the correlation among immune response to SARS-CoV-2 infection, clinical evolution, and PET results. Under the strict safety measures implemented at the PET center, the number of potentially SARS-CoV-2–positive patients undergoing PET/CT was very low (1.6%), and no staff member has been diagnosed with infection as of April 30, 2020. |
format | Online Article Text |
id | pubmed-7308791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73087912020-06-23 Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer Scarlattei, Maura Baldari, Giorgio Silva, Mario Bola, Stefano Sammartano, Antonino Migliari, Silvia Graziani, Tiziano Cidda, Carla Sverzellati, Nicola Ruffini, Livia Tumori Short Communication INTRODUCTION: In January 2020, the coronavirus disease 2019 (COVID-19) outbreak in Italy necessitated rigorous application of more restrictive safety procedures in the management and treatment of patients with cancer to ensure patient and staff protection. Identification of respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was a challenge during the pandemic owing to a large number of asymptomatic or mildly symptomatic patients. METHODS: We report 5 patients with unknown SARS-CoV-2 infection undergoing positron emission tomography (PET)/computed tomography (CT) with radiopharmaceuticals targeting different tumor processes: (18)F-FDG, (18)F-choline (FCH), and (68)Ga-PSMA. RESULTS: In all patients, PET/CT showed increased tracer uptake in the lungs corresponding to CT findings of SARS-CoV-2 pneumonia. Quantitative assessment of tracer uptake showed more elevated values for the glucose analogue (18)F-FDG (mean SUVmax 5.4) than for the other tracers (mean SUVmax 3.5). CONCLUSIONS: Our findings suggest that PET/CT is a sensitive modality to hypothesize SARS-CoV-2 pneumonia in patients with cancer, even when asymptomatic. More data are needed to verify the correlation among immune response to SARS-CoV-2 infection, clinical evolution, and PET results. Under the strict safety measures implemented at the PET center, the number of potentially SARS-CoV-2–positive patients undergoing PET/CT was very low (1.6%), and no staff member has been diagnosed with infection as of April 30, 2020. SAGE Publications 2020-06-22 2020-08 /pmc/articles/PMC7308791/ /pubmed/32567505 http://dx.doi.org/10.1177/0300891620935983 Text en © Fondazione IRCCS Istituto Nazionale dei Tumori 2020 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Short Communication Scarlattei, Maura Baldari, Giorgio Silva, Mario Bola, Stefano Sammartano, Antonino Migliari, Silvia Graziani, Tiziano Cidda, Carla Sverzellati, Nicola Ruffini, Livia Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer |
title | Unknown SARS-CoV-2 pneumonia detected by PET/CT in
patients with cancer |
title_full | Unknown SARS-CoV-2 pneumonia detected by PET/CT in
patients with cancer |
title_fullStr | Unknown SARS-CoV-2 pneumonia detected by PET/CT in
patients with cancer |
title_full_unstemmed | Unknown SARS-CoV-2 pneumonia detected by PET/CT in
patients with cancer |
title_short | Unknown SARS-CoV-2 pneumonia detected by PET/CT in
patients with cancer |
title_sort | unknown sars-cov-2 pneumonia detected by pet/ct in
patients with cancer |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308791/ https://www.ncbi.nlm.nih.gov/pubmed/32567505 http://dx.doi.org/10.1177/0300891620935983 |
work_keys_str_mv | AT scarlatteimaura unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT baldarigiorgio unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT silvamario unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT bolastefano unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT sammartanoantonino unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT migliarisilvia unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT grazianitiziano unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT ciddacarla unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT sverzellatinicola unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer AT ruffinilivia unknownsarscov2pneumoniadetectedbypetctinpatientswithcancer |